|
Condensed Consolidated Financial Statement Detail (Details)
|
3 Months Ended | 3 Months Ended | 3 Months Ended | 3 Months Ended | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2013
USD ($)
|
Mar. 31, 2012
|
Dec. 31, 2012
USD ($)
|
Feb. 28, 2010
Five year warrants issued in February 2010 [Member]
USD ($)
|
Mar. 31, 2013
Five year warrants issued in March 2012 [Member]
USD ($)
|
Mar. 31, 2013
Five year warrants issued in March 2012 [Member]
|
Dec. 31, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
|
Mar. 31, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
|
Jun. 30, 2009
Warrants issued to private investors [Member]
USD ($)
|
Mar. 31, 2013
Options Contract [Member]
USD ($)
|
Mar. 31, 2012
Options Contract [Member]
USD ($)
|
Mar. 31, 2013
Options Contract [Member]
EUR (€)
|
Mar. 31, 2013
Option Contract 1 [Member]
EUR (€)
|
Mar. 31, 2013
Option Contract 2 [Member]
EUR (€)
|
Mar. 31, 2013
Demand Deposits [Member]
USD ($)
|
Dec. 31, 2012
Demand Deposits [Member]
USD ($)
|
Mar. 31, 2013
Money Market Funds [Member]
USD ($)
|
Dec. 31, 2012
Money Market Funds [Member]
USD ($)
|
Mar. 31, 2013
Common stock options and restricted stock units [Member]
|
Mar. 31, 2012
Common stock options and restricted stock units [Member]
|
Mar. 31, 2013
Warrants for common stock [Member]
|
Mar. 31, 2012
Warrants for common stock [Member]
|
||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||||||||||||||||||||||
| Antidilutive securities excluded from computation of earnings per share (in shares) | 22,635,000 | 11,179,000 | 6,459,000 | 5,722,000 | 16,176,000 | 5,457,000 | |||||||||||||||||||
| Cash and Cash Equivalents [Line Items] | |||||||||||||||||||||||||
| Cash equivalents | $ 12,400,000 | $ 7,800,000 | $ 38,000,000 | $ 37,500,000 | |||||||||||||||||||||
| Short-term Investments [Abstract] | |||||||||||||||||||||||||
| Short-term investments, U.S. treasury securities | 19,996,000 | 39,987,000 | [1] | ||||||||||||||||||||||
| Derivative [Line Items] | |||||||||||||||||||||||||
| Notional amount of derivative liability | 15,000,000 | ||||||||||||||||||||||||
| Number of foreign exchange option contracts | 2 | ||||||||||||||||||||||||
| Derivative, amount of hedged item | 1,500,000 | 15,000,000 | |||||||||||||||||||||||
| Derivative, premiums | 1,500,000 | ||||||||||||||||||||||||
| Derivative fair value | 300,000 | ||||||||||||||||||||||||
| Derivative, loss | 200,000 | 300,000 | |||||||||||||||||||||||
| Accrued liabilities [Abstract] | |||||||||||||||||||||||||
| Accrued payroll and other benefits | 2,169,000 | 2,461,000 | |||||||||||||||||||||||
| Accrued management incentive compensation | 1,086,000 | 3,978,000 | |||||||||||||||||||||||
| Accrued clinical trial costs | 746,000 | 4,702,000 | |||||||||||||||||||||||
| Other | 1,409,000 | 1,904,000 | |||||||||||||||||||||||
| Total | 5,410,000 | 13,045,000 | [1] | ||||||||||||||||||||||
| Class of Warrant or Right [Line Items] | |||||||||||||||||||||||||
| Warrants outstanding (in shares) | 1,260,000 | 14,265,970 | 14,834,577 | 347,826 | |||||||||||||||||||||
| Exercise price (in dollars per share) | $ 10.50 | $ 1.76 | $ 19.50 | ||||||||||||||||||||||
| Fair value of warrant liability | 33,000 | 27,800,000 | 15,000,000 | ||||||||||||||||||||||
| Gain (loss) on revaluation of warrant liability | $ 12,800,000 | ||||||||||||||||||||||||
|
|||||||||||||||||||||||||